Sydney, Australia (CU)_ SHINE Technologies, a future-generation nuclear technology business, and Telix Pharmaceuticals, an Australian bio-pharmaceutical business, have entered into a clinical supply agreement under which SHINE will supply Telix with non-carrier-added lutetium-177 or Lu-177 which will be used in the clinical development of possible new medications for the treatment of prostate and kidney cancer. SHINE will instantly begin delivery of n.c.a. Lu-177 for clinical studies of Telix’s therapeutic candidates TLX591 (177Lu-rosopatamab for advanced prostate cancer) and TLX250 (177Lu-girentuximab for kidney cancer), with a special emphasis on the US market.
Greg Piefer, founder and CEO of SHINE, expressed delight over the partnership. He said, “There continues to be a growing, critical need for more effective treatment of metastatic or late-stage cancers. Our exciting partnership with Telix allows us to bring hope to these patients as we continue to help deliver Lu-177 for highly precise treatments that produce little damage in the tissue around treatment sites.”
The Therapeutics branch of SHINE manufactures n.c.a. Lu-177, which is a low-energy beta-particle emitter that may be used in conjunction with a targeting molecule such as an antibody or peptide to directly fight and irradiate cancer cells. Numerous Lu-177 treatments are now being developed to treat all types of cancers and may give an additional therapy option for individuals who have failed to respond to prior therapeutic choices.
Gabriel Liberatore, chief operating officer of Telix, expressed optimism over the collaboration. He said, “SHINE’s investment in high quality isotope production places them at the forefront of the radiopharmaceutical supply chain with particular strength in servicing the U.S. market. The agreement with SHINE supports our goal to establish a global supply chain with the capacity and reliability to support an increasing level of clinical activity through Telix-sponsored and investigator-led studies and to scale-up to the commercial stage.”
